How's that RS working out? Think the NASDAQ crowd is easily conned? Stay tuned. Another CRL is right around the corner. Happy holidays and dreams of profits...LOL
The only losers on this message board are those who believe the lies being told by this company. Good luck with your "lowlife" theory. Hope that works out for you better than your investment in this scam.
goffyjay joined the board in August.... Meantime, I've been here for six years. Guess who knows more about these thieves?
After attending the first Adcom I have no confidence the next one will result in a unanimous approval vote. I believe another CRL is more likely due to an insufficient REMS, a weakness the panel won't overlook. Still lots to be made trading this junk paper but it's not smart to be caught holding when the other shoe drops. The "Street's" on board now with a leading pumper article, so that means the manipulation "fix" is being postured. Beware.
Prepare for a major price implosion. Titan's REMS remains an unmitigated failure. The FDA won't pass it, even if the panel votes to approve these Buprenorphine ethyl rods (Probuphine) once again. No way does Titan escape another CRL.
Thanks dirt sack. Amusing to see you're about as bad at math as you are at investing. I have no need to bash a company I've followed daily since 09. I call Titan and the scoundrels that run it as they are.....and I have not been wrong about Titan....not even once...in seven years. So good luck with your 'investment.' Meantime, expect another CRL....it's on the way.
Given your response, it would seem that you're the one who is a JOKER. Explain the REMS since it's not "rocket science," as you state. Questions: Where will these implants be performed on patients? What training will be required? How many patients will the FDA allow each Dr., since the rods contain burprenorphine and given tighter scheduling controls on dispensaries of this drug. Where will the rods be dispensed to patients, given FDA requirements regarding their storage? What does the dispensary to doctor to patient procedure entail, in detail? How about patient specifics like the number each Dr. may treat, given strict per patient drug dispensary guidelines. How about patient surgical follow-ups and rod removal? These are all questions (and more) to be addressed in the REMS, a document whose satisfaction must 'pass muster' with the FDA, not just the Adcom. It's not enough to have a drug approval, which by the way, buprenorphine (in Probuphine) is already approved. One must have a satisfactory REMS. The insufficent REMS was the core reason for the last CRL and it will likely be the principal reason for the next one. I was at that first Adcom panel in MD, in person, so good luck calling me some kind of basher. I've followed this company closely, almost daily, for over half a decade. A person who just dismisses my opinion is a fool, or more likely, some pumping day trader.
They could literally give it away and nobody would bite. The therapy is now dated, with cheaper and better (more easily dispensed) alternatives readily available. Titan missed its commercialization window by about 15 months.
No, no they're not. And it's not very likely this will be approved, since as I've stated on numerous occasions, the REMS remains inadequate to pass FDA muster and there's not very much Titan can do about it (Read the CRL from the FDA)......
I sat next to one at the first Bethesda panel.....his pleas fell on deaf ears then, as they will most certainly do now.....
The REMS is insufficient, as before, which is the reason for the AdComm....and the forthcoming 2nd CRL.....
I know a GREAT deal more than you on the subject and I've documented thousands of posts here since 2009 to prove it. Say what you will but their REMS is insufficient, the reason the FDA has called a second AdComm.....but as a short, you know that don't you?
Careful with this one....things are not as they appear. Having been a by-standing party to this company's drama daily since 2009, it's my considered and very informed opinion that this device will not be approved..... The much discussed REMS remains insufficient to satisfy the FDA, even if it passes a panel again, but there also are numerous holes in their data, the science itself is a bit shaky, plus it's a most inopportune and politically incorrect time to be requesting scheduling exceptions of one of the most misdirected and abused drugs in the treatment arena (buprenorphine....the main component of their Probuphine rods).